BA
BPMC

BlackRock Advisors’s Blueprint Medicines BPMC Stock Holding History

BlackRock Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$295K Sell
10,523
-69
-0.7% -$2.08K ﹤0.01% 2509
2016
Q3 		$315K Buy
10,592
+2,347
+28% +$58.3K ﹤0.01% 2421
2016
Q2 		$167K Buy
8,245
+4,040
+96% +$73.4K ﹤0.01% 2702
2016
Q1 		$76K Buy
4,205
+330
+9% +$5.73K ﹤0.01% 3038
2015
Q4 		$102K Sell
3,875
-27,715
-88% -$624K ﹤0.01% 2910
2015
Q3 		$674K Sell
31,590
-988
-3% -$27.3K ﹤0.01% 1971
2015
Q2 		$863K Buy
+32,578
New +$930K ﹤0.01% 1767

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock Advisors's BPMC Position: Q4 2016 in Review

BlackRock Advisors reduced its Blueprint Medicines (BPMC) stake by 0.65% in Q4 2016, selling an estimated $2.08K and leaving 10,523 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #2509.

BlackRock Advisors first reported a position in BPMC in Q2 2015 and has held it in 7 quarters since. The position peaked at $863K in Q2 2015. 103 funds tracked by Wall St. Rank hold BPMC as of Q4 2016.

  • BlackRock Advisors held 10,523 shares of Blueprint Medicines worth $295K as of Q4 2016.
  • BlackRock Advisors sold 69 Blueprint Medicines shares in Q4 2016, an estimated $2.08K.
  • Blueprint Medicines made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2509 holding.
  • BlackRock Advisors first reported a position in Blueprint Medicines in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Advisors's Blueprint Medicines position peaked at $863K in Q2 2015.
  • 103 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.